Altre lingue Spero Therapeutics, Inc.

Azioni

SPRO

US84833T1034

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/07/2024			Variaz. 5gg	Var. 1 gen.
1,48 ^USD	-1,33%		+8,82%	+0,68%

15/05	Spero Therapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
13/03	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/07
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell 3000E Growth Index	01/07
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell Microcap Growth Index	01/07
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Value Index	01/07
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Value Index	01/07
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/06
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference	16/05
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M	15/05
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update	15/05
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024	08/05
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	13/03
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update	13/03
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	06/03
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections	28/02
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference	26/02
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	09/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spero Therapeutics, Inc.

Azioni

SPRO

US84833T1034

Altre lingue

Filtri